Document Detail

Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
MedLine Citation:
PMID:  22345418     Owner:  NLM     Status:  In-Data-Review    
Purpose The impact of a quality-improvement (QI) initiative to decrease the risk of bleeding in renally impaired patients receiving enoxaparin prophylaxis for venous thromboembolism (VTE) was evaluated. Methods A retrospective cohort with a before-and-after study design was employed. Inclusion criteria included age over 40 years, hospitalization exceeding six days, treatment with enoxaparin or unfractionated heparin (UFH), and acute or chronic renal insufficiency. Major bleeding included fatal bleeding, symptomatic bleeding requiring hemodynamic support or causing a decrease of 2 g/dL or more in hemoglobin concentration, or bleeding leading to the transfusion of at least 2 units of packed red blood cells. The QI intervention restricted enoxaparin use in patients with a creatinine clearance (CL(cr)) concentration of <30 mL/min and recommended UFH instead. Results The rate of major bleeding in the preintervention group was 13.5% with enoxaparin compared with 4.1% with UFH (p = 0.005). The relative risk (RR) of bleeding with enoxaparin compared with UFH was 3.21 (95% confidence interval [CI], 1.40-7.34). In patients with a CL(cr) concentration of <30 mL/min, the RR of bleeding with enoxaparin compared with UFH was 4.68 (95% CI, 1.06-20.59). The rate of major bleeding in the postintervention period was 9.5% with enoxaparin or 4.5% with UFH (p = 0.15). The RR of bleeding in the postintervention period was 0.64 (95% CI, 0.37-1.12). Conclusion A QI initiative that eliminated the use of enoxaparin for prophylaxis of VTE in patients with renal impairment resulted in lower rates of major bleeding associated with pharmacologic prophylaxis. No differences in the rate of inhospital VTE as a result of the intervention were observed.
Khaled A Elsaid; Christine M Collins
Related Documents :
22574818 - High tibial osteotomy in sweden, 1998-2007: a population-based study of the use and rat...
21646908 - Graft rejection after femtosecond laser-assisted deep anterior lamellar keratoplasty: r...
22619668 - Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinde...
22882768 - Clinical significance of induced atrial tachycardia after termination of longstanding p...
25054568 - Laparoscopic roux-en-y gastric bypass for type 2 diabetes mellitus in nonobese chinese ...
18043568 - Mini-invasive techniques for the treatment of female stress urinary incontinence.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  69     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  390-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Liraglutide-associated acute pancreatitis.
Next Document:  Development of a residency interviewing preparatory seminar.